TABLE 1.

Demographic, Comorbidity, Medication, Hospitalization, and Mortality Data of the Study Patients

	Nonprogressive (n = 51)	Progressive (n = 123)	P
Age, median (min-max), y	68 (28–92)	68 (34–91)	0.899
Sex, n (%)
Male	28 (54.9%)	78 (63.4%)	0.295
Female	23 (45.1%)	45 (36.6%)	0.310
Comorbidities, n (%)
Hypertension	26 (51%)	47 (38.2%)	0.132
Diabetes mellitus	14 (27.5%)	42 (34.1%)	0.477
COPD/asthma	11 (21.6%)	25 (20.3%)	0.840
Coronary artery disease	12 (23.5%)	24 (20.3%)	0.544
Previous history of malignancy	1 (2%)	2 (1.6%)	0.877
Medication, n (%)
Favipiravir	50 (98%)	118 (95.9%)	0.489
Hydroxychloroquine	11 (21.6%)	37 (30.1%)	0.253
Methylprednisolone	13 (25.5%)	81 (65.9%)	<0.001
Tocilizumab	0	6 (4.9%)
Antibiotics	51 (100%)	123 (100%)
Low-molecular weight heparin	51 (100%)	123 (100%)
ICU, n (%)	2 (3.9%)	123 (100%)	<0.001
Dead, n (%)	4 (7.8%)	71 (57.7%)	<0.001

COPD indicates chronic obstructive pulmonary disease.